Validation of the LupusPRO in Chinese Patients From Hong Kong With Systemic Lupus Erythematosus

Arthritis Care and Research

Volumn 67, Issue 2, 2015, Pages 297-304

  Mok, Chi Chiu ^a   Kosinski, Mark ^b   Ho, Ling Yin ^a   Chan, Kar Li ^a   Jolly, Meenakshi ^c  

^a TUEN MUN HOSPITAL   (Hong Kong)

^b QualityMetric Incorporated   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHINESE; DISEASE ACTIVITY; FEMALE; HONG KONG; HUMAN; LUPUSPRO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PSYCHOMETRY; QUESTIONNAIRE; SHORT FORM 36; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION PROCESS; ASIAN CONTINENTAL ANCESTRY GROUP; LANGUAGE; MIDDLE AGED; PROCEDURES; QUALITY OF LIFE; REPRODUCIBILITY; STANDARDS; VALIDATION STUDY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HONG KONG; HUMANS; LANGUAGE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT OUTCOME ASSESSMENT; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS;

EID: 84922041419     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22448     Document Type: Article

References (34)

1. Mok CC. Emerging biological therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2014;19:303-22.
2. Mok CC. Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese. Lupus 2011;20:767-71.
3. Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II: role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2004;43:1580-6.
4. Rinaldi S, Doria A, Salaffi F, Ermani M, Iaccarino L, Ghirardello A, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I: relationship between physical and mental dimension and impact of age. Rheumatology (Oxford) 2004;43:1574-9.
5. Ruperto N, Buratti S, Duarte-Salazar C, Pistorio A, Reiff A, Bernstein B, et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Rheum 2004;51:458-64.
6. Mok CC, Ho LY, Cheung MY, Yu KL, To CH. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009;38:121-7.
7. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005;32:1706-8.
8. Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, et al, for the BLISS-52 and -76 Study Groups. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014;73:838-44.
9. Alarcon GS, McGwin G Jr, Uribe A, Friedman AW, Roseman JM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII: predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004;51:465-74.
10. Strand V, Petri M, Kalunian K, Gordon C, Wallace DJ, Hobbs K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) 2014;53:502-11.
11. Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 2012;42:56-65.
12. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972-9.
13. Kaya A, Goker B, Cura ES, Tezcan ME, Tufan A, Mercan R, et al. Turkish LupusPRO: cross-cultural validation study for lupus. Clin Rheumatol 2014;33:1079-84.
14. Jolly M, Toloza S, Block J, Mikolaitis R, Kosinski M, Wallace D, et al. Spanish LupusPRO: cross-cultural validation study for lupus. Lupus 2013;22:431-6.
15. Bourre-Tessier J, Clarke AE, Mikolaitis-Preuss RA, Kosinski M, Bernatsky S, Block JA, et al. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada. J Rheumatol 2013;40:1327-33.
16. Navarra SV, Tanangunan RM, Mikolaitis-Preuss RA, Kosinski M, Block JA, Jolly M. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines. Lupus 2013;22:262-7.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
18. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417-32.
19. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. International consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes: results of the COSMIN study. J Clin Epidemol 2010;63:737-45.
20. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
21. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liant M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
22. Hu LT, Bentler PM. Cutoff criteria for fit indices in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Modeling 1999;6:1-55.
23. Jackson DL, Gillaspy JA, Purc-Stephenson R. Reporting practices in confirmatory factor analysis: an overview and some recommendations. Psychol Methods 2009;14:6-23.
24. MacCallum RC, Browne MW, Sugawara HM. Power analysis and determination of sample size for covariance structure modeling. Psychol Methods 1996;1:130-49.
25. Steinberg L, Thissen D. Uses of item response theory and the testlet concept in the measurement of psychopathology. Psychol Methods 1996;1:81-97.
26. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV: outcome measures in rheumatology. Lupus 2000;9:322-7.
27. Gordon C, Isenberg D, Lerstrom K, Norton Y, Nikai E, Pushparajah DS, et al. The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology (Oxford) 2013;52:2292-301.
28. Jolly M, Utset TO. Can disease specific measures for systemic lupus erythematosus predict patients' health related quality of life? Lupus 2004;13:924-6.
29. Kuriya B, Gladman DD, Ibanez D, Urowitz MB. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008;59:181-5.
30. Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol 2009;36:1209-16.
31. Gallop K, Nixon A, Swinburn P, Sterling KL, Naegeli AN, Silk ME. Development of a conceptual model of health-related quality of life for systemic lupus erythematosus from the patient's perspective. Lupus 2012;21:934-43.
32. Touma Z, Urowitz MB, Gladman DD. Outcome measures in systemic lupus erythematosus. Indian J Rheumatol 2013;8 Suppl 1:S46-S53.
33. Jolly M, Kosinski M, Toloza S, Block JA, Mikolaitis RA, Duran-Barragan S, et al. Equivalence of various language versions of lupus specific patient reported outcomes measure (LupusPRO) [abstract]. Arthritis Rheum 2012;Suppl 10:S607.
34. Jolly M, Cornejo J, Mikolaitis RA, Block JA. LupusPRO and responsiveness to changes in health status and disease activity over time [abstract]. Arthritis Rheum 2011;Suppl 10:S898.